Mortality rate and acute kidney injury prevalence reduction in COVID-19 critical patients treated with hemoperfusion

Introduction: Coronavirus disease 2019 (COVID‑19) induces organic damage mainly through the patient’s immune overreaction. Hemoperfusion (HPF) can remove infl ammatory cytokines and can reduce the negative effects of cytokine storm in COVID‑19. We compared the mortality rate, infl ammatory response,...

Full description

Autores:
Barriga-Moreno, Adriana P.
Lozano Sánchez, Marcela
Barón-Álvarez, Rafael A.
Córdoba, Juan P.
Aroca-Martinez, Gustavo
Dianda, Daniela
González-Torres, Henry Joseth
Musso, Carlos
Tipo de recurso:
Fecha de publicación:
2024
Institución:
Universidad Simón Bolívar
Repositorio:
Repositorio Digital USB
Idioma:
eng
OAI Identifier:
oai:bonga.unisimon.edu.co:20.500.12442/15895
Acceso en línea:
https://hdl.handle.net/20.500.12442/15895
https://pubmed.ncbi.nlm.nih.gov/38645920/
Palabra clave:
Acute kidney injury
COVID‑19
Hemoperfusion
Rights
openAccess
License
Attribution-NonCommercial-NoDerivs 3.0 United States
id USIMONBOL2_66f1d57060d5052e6e119b184d8bda97
oai_identifier_str oai:bonga.unisimon.edu.co:20.500.12442/15895
network_acronym_str USIMONBOL2
network_name_str Repositorio Digital USB
repository_id_str
dc.title.eng.fl_str_mv Mortality rate and acute kidney injury prevalence reduction in COVID-19 critical patients treated with hemoperfusion
title Mortality rate and acute kidney injury prevalence reduction in COVID-19 critical patients treated with hemoperfusion
spellingShingle Mortality rate and acute kidney injury prevalence reduction in COVID-19 critical patients treated with hemoperfusion
Acute kidney injury
COVID‑19
Hemoperfusion
title_short Mortality rate and acute kidney injury prevalence reduction in COVID-19 critical patients treated with hemoperfusion
title_full Mortality rate and acute kidney injury prevalence reduction in COVID-19 critical patients treated with hemoperfusion
title_fullStr Mortality rate and acute kidney injury prevalence reduction in COVID-19 critical patients treated with hemoperfusion
title_full_unstemmed Mortality rate and acute kidney injury prevalence reduction in COVID-19 critical patients treated with hemoperfusion
title_sort Mortality rate and acute kidney injury prevalence reduction in COVID-19 critical patients treated with hemoperfusion
dc.creator.fl_str_mv Barriga-Moreno, Adriana P.
Lozano Sánchez, Marcela
Barón-Álvarez, Rafael A.
Córdoba, Juan P.
Aroca-Martinez, Gustavo
Dianda, Daniela
González-Torres, Henry Joseth
Musso, Carlos
dc.contributor.author.none.fl_str_mv Barriga-Moreno, Adriana P.
Lozano Sánchez, Marcela
Barón-Álvarez, Rafael A.
Córdoba, Juan P.
Aroca-Martinez, Gustavo
Dianda, Daniela
González-Torres, Henry Joseth
Musso, Carlos
dc.subject.eng.fl_str_mv Acute kidney injury
COVID‑19
Hemoperfusion
topic Acute kidney injury
COVID‑19
Hemoperfusion
description Introduction: Coronavirus disease 2019 (COVID‑19) induces organic damage mainly through the patient’s immune overreaction. Hemoperfusion (HPF) can remove infl ammatory cytokines and can reduce the negative effects of cytokine storm in COVID‑19. We compared the mortality rate, infl ammatory response, and acute kidney injury (AKI) prevalence among patients suffering from respiratory insufficiency secondary to COVID‑19 treated with and without HPF with HA330 cartridge. Methods: Mortality rate, serum creatinine, and ferritin values were compared between patients suffering from respiratory insufficiency secondary to COVID‑19 who received conventional treatment and another group of patients who additionally received four sessions of HPF with HA330. Results: Of 116 patients suffering from acute respiratory insufficiency secondary to severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2), one group (n: 84) received support treatment and the other group (n: 32) additionally received HPF with HA330 cartridge. Both groups had no renal disease and similar age and comorbidities at admission, except for obesity and mechanical ventilation requirement, which were significantly higher in the HPF group. Mortality rate (61% vs. 31%, P: 0.008), serum creatinine (1.4 vs. 0.5 mg/dl, P < 0.001), and post‑HPF serum ferritin (2868 vs. 1675, P < 0.001) were significantly lower in the HPF group. Conclusion: Mortality rate, serum ferritin, and AKI were significantly reduced in critical COVID‑19 patients who received HPF with HA330 cartridge than in those who did not receive it. These results were obtained despite the HPF group risk factors, such as obesity and mechanical ventilation, worsening its prognosis.
publishDate 2024
dc.date.accessioned.none.fl_str_mv 2024-10-24T20:07:16Z
dc.date.available.none.fl_str_mv 2024-10-24T20:07:16Z
dc.date.issued.none.fl_str_mv 2024
dc.type.coarversion.fl_str_mv http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.coar.fl_str_mv http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.driver.none.fl_str_mv info:eu-repo/semantics/article
dc.type.spa.none.fl_str_mv Artículo científico
dc.identifier.citation.eng.fl_str_mv Barriga-Moreno AP, Lozano-Sanchez M, Barón-Alvarez RA, Cordoba JP, Aroca-Martinez G, Dianda D, Gonzalez-Torres H, Musso CG. Mortality Rate and Acute Kidney Injury Prevalence Reduction in COVID-19 Critical Patients Treated with Hemoperfusion. Indian J Nephrol. 2024 Jan-Feb;34(1):56-58. doi: 10.4103/ijn.ijn_175_22
dc.identifier.issn.none.fl_str_mv 09714065 (Impreso)
19983662 (Electrónico)
dc.identifier.uri.none.fl_str_mv https://hdl.handle.net/20.500.12442/15895
dc.identifier.doi.none.fl_str_mv DOI: 10.4103/ijn.ijn_175_22
dc.identifier.url.none.fl_str_mv https://pubmed.ncbi.nlm.nih.gov/38645920/
identifier_str_mv Barriga-Moreno AP, Lozano-Sanchez M, Barón-Alvarez RA, Cordoba JP, Aroca-Martinez G, Dianda D, Gonzalez-Torres H, Musso CG. Mortality Rate and Acute Kidney Injury Prevalence Reduction in COVID-19 Critical Patients Treated with Hemoperfusion. Indian J Nephrol. 2024 Jan-Feb;34(1):56-58. doi: 10.4103/ijn.ijn_175_22
09714065 (Impreso)
19983662 (Electrónico)
DOI: 10.4103/ijn.ijn_175_22
url https://hdl.handle.net/20.500.12442/15895
https://pubmed.ncbi.nlm.nih.gov/38645920/
dc.language.iso.none.fl_str_mv eng
language eng
dc.rights.eng.fl_str_mv Attribution-NonCommercial-NoDerivs 3.0 United States
dc.rights.coar.fl_str_mv http://purl.org/coar/access_right/c_abf2
dc.rights.uri.none.fl_str_mv http://creativecommons.org/licenses/by-nc-nd/3.0/us/
dc.rights.accessrights.none.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv Attribution-NonCommercial-NoDerivs 3.0 United States
http://creativecommons.org/licenses/by-nc-nd/3.0/us/
http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv openAccess
dc.format.mimetype.none.fl_str_mv pdf
dc.publisher.eng.fl_str_mv Wolters Kluwer
Medknow Publications
institution Universidad Simón Bolívar
bitstream.url.fl_str_mv https://bonga.unisimon.edu.co/bitstreams/3dcc987d-4655-4562-bdd3-22b1385caa9a/download
https://bonga.unisimon.edu.co/bitstreams/98da9b9a-b6e4-45e6-8275-c379330273b1/download
https://bonga.unisimon.edu.co/bitstreams/bef7189f-7e0c-41e1-8498-1ffc09904862/download
https://bonga.unisimon.edu.co/bitstreams/f59dbed9-e4d2-4d2e-ac94-67457a3d5583/download
https://bonga.unisimon.edu.co/bitstreams/cad931f4-1f90-4c0a-aeb0-f66bd0dcf533/download
bitstream.checksum.fl_str_mv 7040df93d50cbf1d900eba74463b06a1
2f656a26de8af8c32aaacd5e2a33538c
733bec43a0bf5ade4d97db708e29b185
17f6bb68a68136a4069a6f9234a0700d
8ed6de63ceec942325b41c3d9259e908
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
MD5
repository.name.fl_str_mv Repositorio Digital Universidad Simón Bolívar
repository.mail.fl_str_mv repositorio.digital@unisimon.edu.co
_version_ 1814076155088601088
spelling Barriga-Moreno, Adriana P.02902934-8ba5-43e9-9389-b613daa5e458-1Lozano Sánchez, Marcelab5a61e64-b8f4-4b32-a4f1-83859dac21f7600Barón-Álvarez, Rafael A.2b9b7e7b-d576-4f13-bc3a-37c3ad6d162e-1Córdoba, Juan P.3dbcf0a4-89ae-409f-9d1e-daf8bb6bb9d4-1Aroca-Martinez, Gustavo2fb7c7c2-3dc2-433b-8cf5-b572c74f9ce3600Dianda, Daniela60417dd4-9cb5-4302-96a5-caf3ab281eab-1González-Torres, Henry Joseth62b241c2-eb59-490a-9176-090eff514358600Musso, Carlosbdd9d24a-f657-4e3e-9ceb-26a86e19593d6002024-10-24T20:07:16Z2024-10-24T20:07:16Z2024Barriga-Moreno AP, Lozano-Sanchez M, Barón-Alvarez RA, Cordoba JP, Aroca-Martinez G, Dianda D, Gonzalez-Torres H, Musso CG. Mortality Rate and Acute Kidney Injury Prevalence Reduction in COVID-19 Critical Patients Treated with Hemoperfusion. Indian J Nephrol. 2024 Jan-Feb;34(1):56-58. doi: 10.4103/ijn.ijn_175_2209714065 (Impreso)19983662 (Electrónico)https://hdl.handle.net/20.500.12442/15895DOI: 10.4103/ijn.ijn_175_22https://pubmed.ncbi.nlm.nih.gov/38645920/Introduction: Coronavirus disease 2019 (COVID‑19) induces organic damage mainly through the patient’s immune overreaction. Hemoperfusion (HPF) can remove infl ammatory cytokines and can reduce the negative effects of cytokine storm in COVID‑19. We compared the mortality rate, infl ammatory response, and acute kidney injury (AKI) prevalence among patients suffering from respiratory insufficiency secondary to COVID‑19 treated with and without HPF with HA330 cartridge. Methods: Mortality rate, serum creatinine, and ferritin values were compared between patients suffering from respiratory insufficiency secondary to COVID‑19 who received conventional treatment and another group of patients who additionally received four sessions of HPF with HA330. Results: Of 116 patients suffering from acute respiratory insufficiency secondary to severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2), one group (n: 84) received support treatment and the other group (n: 32) additionally received HPF with HA330 cartridge. Both groups had no renal disease and similar age and comorbidities at admission, except for obesity and mechanical ventilation requirement, which were significantly higher in the HPF group. Mortality rate (61% vs. 31%, P: 0.008), serum creatinine (1.4 vs. 0.5 mg/dl, P < 0.001), and post‑HPF serum ferritin (2868 vs. 1675, P < 0.001) were significantly lower in the HPF group. Conclusion: Mortality rate, serum ferritin, and AKI were significantly reduced in critical COVID‑19 patients who received HPF with HA330 cartridge than in those who did not receive it. These results were obtained despite the HPF group risk factors, such as obesity and mechanical ventilation, worsening its prognosis.pdfengWolters KluwerMedknow PublicationsAttribution-NonCommercial-NoDerivs 3.0 United Stateshttp://creativecommons.org/licenses/by-nc-nd/3.0/us/info:eu-repo/semantics/openAccesshttp://purl.org/coar/access_right/c_abf2Acute kidney injuryCOVID‑19HemoperfusionMortality rate and acute kidney injury prevalence reduction in COVID-19 critical patients treated with hemoperfusioninfo:eu-repo/semantics/articleArtículo científicohttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_2df8fbb1Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID‑19 in Wuhan, China: A retrospective cohort Study. Lancet 2020;395:1054‑62.Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID‑19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 2020;46:846‑8.Driggin E, Madhavan MV, Bikdeli B, Chuich T, Laracy J, Bondi‑Zoccai G, et al. Cardiovascular considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID‑19) pandemic. J Am Coll Cardiol 2020;75:2352‑71.Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of immune response in patients with COVID‑19 in Wuhan, China. Clint Infect Dis 2020;71:762‑8.Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID‑19: Consider cytokine storm syndromes and immunosuppression. Lancet 2020;395:1033‑4.Pomarè‑Montin D, Ankawi G, Lorenzin A, Neri M, Caprara C, Ronco C. Biocompatibility and cytotoxic evaluation of new sorbent cartridges for blood hemoperfusion. Blood Purif 2018;46:187‑95.Ankawi G, Fan W, Pomarè Montin D, Lorenzin A, Neri M, Caprara C, et al. A new series of sorbent devices for multiple clinical purposes: Current evidence and future directions. Blood Purif 2019;47:94‑100.Rampino T, Gregorini M, Perotti L, Ferrari F, Pattonieri EF, Grignano MA, et al. Hemoperfusion with cytosorb as adjuvant therapy in critically ill patients with SARS‑CoV2 pneumonia. Blood Purif 2021;50:566‑71.Huang Z, Wang SR, Su W, Liu JY. Removal of humoral mediators and the effect on the survival of septic patients by hemoperfusion with neutral microporous resin column. Ther Apher Dial 2010;14:596‑602.He Z, Lu H, Jian X, Li G, Xiao D, Meng Q, et al. The efficacy of resin hemoperfusion cartridge on inflammatory responses during adult cardiopulmonary bypass. Blood Purif 2021;1‑7.Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus‑infected pneumonia in Wuhan, China. JAMA 2020;323:1061‑9.Ronco C, Bagshaw SM, Bellomo R, Clark WR, Husain‑Syed F, Kellum JA, et al. Extracorporeal blood purification and organ support in the critically ill patient during COVID‑19 pandemic: Expert review and recommendation. Blood Purif 2021;50:17‑27.Ronco C, Reis T. Kidney involvement in COVID‑19 and rationale for extracorporeal therapies. Nat Rev Nephrol 2020;16:308‑10.Sede BarranquillaORIGINALPDF.pdfPDF.pdfapplication/pdf441790https://bonga.unisimon.edu.co/bitstreams/3dcc987d-4655-4562-bdd3-22b1385caa9a/download7040df93d50cbf1d900eba74463b06a1MD51CC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-8905https://bonga.unisimon.edu.co/bitstreams/98da9b9a-b6e4-45e6-8275-c379330273b1/download2f656a26de8af8c32aaacd5e2a33538cMD52LICENSElicense.txtlicense.txttext/plain; charset=utf-8381https://bonga.unisimon.edu.co/bitstreams/bef7189f-7e0c-41e1-8498-1ffc09904862/download733bec43a0bf5ade4d97db708e29b185MD53TEXTPDF.pdf.txtPDF.pdf.txtExtracted texttext/plain13139https://bonga.unisimon.edu.co/bitstreams/f59dbed9-e4d2-4d2e-ac94-67457a3d5583/download17f6bb68a68136a4069a6f9234a0700dMD54THUMBNAILPDF.pdf.jpgPDF.pdf.jpgGenerated Thumbnailimage/jpeg6379https://bonga.unisimon.edu.co/bitstreams/cad931f4-1f90-4c0a-aeb0-f66bd0dcf533/download8ed6de63ceec942325b41c3d9259e908MD5520.500.12442/15895oai:bonga.unisimon.edu.co:20.500.12442/158952024-10-25 03:03:48.587http://creativecommons.org/licenses/by-nc-nd/3.0/us/Attribution-NonCommercial-NoDerivs 3.0 United Statesopen.accesshttps://bonga.unisimon.edu.coRepositorio Digital Universidad Simón Bolívarrepositorio.digital@unisimon.edu.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